Literature DB >> 29663421

Population Pharmacokinetic Analysis of Busulfan in Japanese Pediatric and Adult HCT Patients.

Atsuko Kawazoe1, Tomoo Funaki1, Seongryul Kim1.   

Abstract

Busulfan is the most common chemotherapy agent used in allogeneic hematopoietic cell transplant (HCT) conditioning regimens. As narrow therapeutic index and interpatient variability exists in the effectiveness and toxicity of conditioning regimens, personalizing intravenous busulfan therapy is desirable. Population pharmacokinetic-based approaches have been applied to therapeutic drug monitoring for the purpose of personalizing therapy. A population pharmacokinetic analysis with the objective of personalizing therapy in Japanese patients was conducted by integrating pediatric patient data with adult patient data. McCune's model, a 2-compartment model that includes maturation of clearance and allometric scaling of clearance and volume of distribution, was used for the analysis. McCune's model could precisely describe the Japanese data, and the estimated parameters were similar to McCune's results for non-Japanese, indicating that there are no racial differences in busulfan pharmacokinetics. Using this model, the plasma concentrations for once-daily dosing were simulated to adapt new dosage regimens for the benefit and convenience of both patients and medical staff. The predicted busulfan concentrations were within the therapeutic range.
© 2018, The American College of Clinical Pharmacology.

Entities:  

Keywords:  allometric scaling; busulfan; maturation function; optimal dosing simulation; population pharmacokinetic analysis

Mesh:

Substances:

Year:  2018        PMID: 29663421     DOI: 10.1002/jcph.1120

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

1.  Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation.

Authors:  Adrin Dadkhah; Sebastian Georg Wicha; Nicolaus Kröger; Alexander Müller; Christoph Pfaffendorf; Maria Riedner; Anita Badbaran; Boris Fehse; Claudia Langebrake
Journal:  Pharmaceutics       Date:  2022-05-27       Impact factor: 6.525

Review 2.  Review of the Pharmacokinetics and Pharmacodynamics of Intravenous Busulfan in Paediatric Patients.

Authors:  Rachael Lawson; Christine E Staatz; Christopher J Fraser; Stefanie Hennig
Journal:  Clin Pharmacokinet       Date:  2020-10-30       Impact factor: 6.447

3.  Population pharmacokinetic model for once-daily intravenous busulfan in pediatric subjects describing time-associated clearance.

Authors:  Rachael Lawson; Christine E Staatz; Christopher J Fraser; Shanti Ramachandran; Lochie Teague; Richard Mitchell; Tracey O'Brien; Stefanie Hennig
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-06-16

Review 4.  Total Body Irradiation Forever? Optimising Chemotherapeutic Options for Irradiation-Free Conditioning for Paediatric Acute Lymphoblastic Leukaemia.

Authors:  Khalil Ben Hassine; Madeleine Powys; Peter Svec; Miroslava Pozdechova; Birgitta Versluys; Marc Ansari; Peter J Shaw
Journal:  Front Pediatr       Date:  2021-12-10       Impact factor: 3.418

Review 5.  Therapeutic Drug Monitoring of Conditioning Agents in Pediatric Allogeneic Stem Cell Transplantation; Where do We Stand?

Authors:  M Y Eileen C van der Stoep; Lisa V E Oostenbrink; Robbert G M Bredius; Dirk Jan A R Moes; Henk-Jan Guchelaar; Juliette Zwaveling; Arjan C Lankester
Journal:  Front Pharmacol       Date:  2022-03-07       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.